Stay updated on PF-06463922 ALK/ROS1 Inhibitor Clinical Trial
Sign up to get notified when there's something new on the PF-06463922 ALK/ROS1 Inhibitor Clinical Trial page.

Latest updates to the PF-06463922 ALK/ROS1 Inhibitor Clinical Trial page
- Check6 days agoChange DetectedNew revision added: v3.4.2, replacing v3.4.1 in the history. No substantive page content changes are evident.SummaryDifference0.0%

- Check14 days agoChange DetectedAn additional revision entry v3.4.1 is added and the previous v3.4.0 entry is removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe page history shows Revision: v3.3.4 in place of the previous v3.3.3. There are no visible changes to the study details or other user-facing content.SummaryDifference0.0%

- Check57 days agoChange DetectedA new Revision: v3.3.3 was added; the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check86 days agoChange DetectedFooter revision tag updated from v3.2.0 to v3.3.2 with no changes to study data or content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check93 days agoChange DetectedRemoved the generic government funding/operational status notice from the page header; the study history and data remain unchanged.SummaryDifference0.3%

Stay in the know with updates to PF-06463922 ALK/ROS1 Inhibitor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06463922 ALK/ROS1 Inhibitor Clinical Trial page.